Moderate Psoriasis Market to Accelerate Substantially, Predicts DelveInsight | Key Companies to Watch Out – Soligenix, Biocon, UCB Pharma, AbbVie, Bristol-Myers Squibb, Amgen, Janssen, Pfizer, KoBioLabs

New York, USA, June 15, 2023 (GLOBE NEWSWIRE) — Moderate Psoriasis Market to Accelerate Substantially, Predicts DelveInsight | Key Companies to Watch Out – Soligenix, Biocon, UCB Pharma, AbbVie, Bristol-Myers Squibb, Amgen, Janssen, Pfizer, KoBioLabs

The expected launch of novel therapies by key companies such as UCB, Bristol Myers Squibb, Dermavant Sciences, Arcutis Biotherapeutics, and others shall fuel the growth of the moderate psoriasis market during the forecast period, i.e., 2022–2032 The moderate psoriasis market size is mainly dominated by biological therapies, which contributes highly towards the overall moderate psoriasis market share.

DelveInsight’s Moderate Psoriasis Market Insights report includes a comprehensive understanding of current treatment practices, moderate psoriasis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Moderate Psoriasis Market Report

• As per DelveInsight analysis, the moderate psoriasis market is expected to grow positively owing to several underline factors during the study period (2019–2032).
• The National Psoriasis Foundation defines, 3% to 10% of patients are affected with moderate psoriasis. However, the severity of psoriasis is also measured by how psoriasis affects a person’s quality of life. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe.
• Leading moderate psoriasis companies such as Soligenix, SFA Therapeutics, Biocon Limited, Biohaven Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, Novartis Pharmaceuticals, UCB Pharma, AbbVie, Bristol-Myers Squibb, Ventyx Biosciences, Inc, Amgen, Meiji Pharma USA Inc., Janssen Research & Development, LLC, Pfizer, KoBioLabs, Alumis Inc, Abcentra, and others are developing novel moderate psoriasis drugs that can be available in the moderate psoriasis market in the coming years.
• Some of the key therapies for moderate psoriasis treatment include Hypericin, SFA002, Stelara, Rimegepant, SCD-044, Secukinumab, Bimekizumab, Risankizumab, BMS-986322, VTX958, Apremilast, ME3183, JNJ-77242113, PF-07038124, KBL697, ESK-001, Orticumab, and others. 

Discover which therapies are expected to grab the major moderate psoriasis market share @ Moderate Psoriasis Market Report

Moderate Psoriasis Overview

Moderate psoriasis is when 3% to 10% of your body has patches. This typically implies your arms and legs, torso, and scalp are affected. It is also deemed moderate if it cannot be controlled with topical medications or has a major influence on your quality of life. Moderate psoriasis has both pediatric and adult-onset, with the former accounting for the majority of occurrences. Plaques differ in their form, distribution, and severity. Psoriatic patients are commonly divided into two categories: mild or moderate-to-severe psoriasis, based on the clinical severity of the lesions, the proportion of affected body surface area, and patient quality of life. Psoriasis affects around 14.8% of pediatric patients. By the age of 15, one-third of all psoriasis cases have occurred. The disease’s prevalence rises linearly, from 0.2% among 1-year-olds to 1.2% among 18-year-olds, but occurrence in children under the age of 10 remains unusual.

Moderate Psoriasis Epidemiology Segmentation

The moderate psoriasis epidemiology section provides insights into the historical and current moderate psoriasis patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The moderate psoriasis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Prevalence of Moderate Psoriasis in Pediatrics
• Prevalence of Moderate Psoriasis in Adults

Download the report to understand which factors are driving moderate psoriasis epidemiology trends @ Moderate Psoriasis Epidemiological Insights

Moderate Psoriasis Treatment Market 

A variety of therapeutic regimens are available for the symptomatic treatment of psoriasis. Patients with moderate psoriasis typically get topical therapies that modify gene transcription, decrease cell proliferation, and encourage keratinocyte differentiation. These cases can be treated topically with a combination of glucocorticoids, vitamin D analogs, and phototherapy. Biologics have emerged as extremely effective therapy choices for individuals in whom standard systemic medicines have failed to generate an appropriate response, are not tolerated due to adverse effects, or are ineffective due to comorbidities. In 2004, the tumor necrosis factor (TNF) antagonist etanercept (Enbrel; Amgen) was licensed as the first biologic treatment for psoriasis.

Etanercept was followed to the market by two TNF inhibitors: infliximab (Remicade; Merck & Co./Janssen Biotech) in 2006 and adalimumab (Humira; AbbVie) in 2008. Humira and Enbrel have their labels expanded to include fingernail psoriasis in adults in 2017 and plaque psoriasis in children aged 4-17 in 2016. CImizia (UCB), licensed by the FDA in 2018, is the most recent entrant into the anti-TNF market for psoriasis. It is the first Fc-free biologic approved by the FDA to treat people with moderate-to-severe plaque psoriasis who are not candidates for systemic treatment or phototherapy. Because of its superior safety and efficacy profile, adalimumab has become the treatment of choice for moderate to severe psoriasis. However, TNF antagonists have been related to infections and cancer, so clinicians must assess the benefits with the risks of using these medications.

To know more about moderate psoriasis treatment, visit @ Moderate Psoriasis Treatment Drugs 

Key Moderate Psoriasis Therapies and Companies

• Hypericin: Soligenix
• SFA002: SFA Therapeutics
• Stelara: Biocon Limited
• Rimegepant: Biohaven Pharmaceuticals, Inc.
• SCD-044: Sun Pharmaceutical Industries Limited
• Secukinumab: Novartis Pharmaceuticals
• Bimekizumab: UCB Pharma
• Risankizumab: AbbVie
• BMS-986322: Bristol-Myers Squibb
• VTX958: Ventyx Biosciences, Inc
• Apremilast: Amgen
• ME3183: Meiji Pharma USA Inc.
• JNJ-77242113: Janssen Research & Development, LLC
• PF-07038124: Pfizer
• KBL697: KoBioLabs
• ESK-001: Alumis Inc
• Orticumab: Abcentra

Learn more about the FDA-approved drugs for moderate psoriasis @ Drugs for Moderate Psoriasis Treatment 

Moderate Psoriasis Market Dynamics

The moderate psoriasis market is expected to change in the coming years. The moderate psoriasis market has been lucrative for drug development, resulting in a variety of approved treatments with varied modes of action to treat the disease. The dynamics of the moderate psoriasis market have begun to shift in recent years, with a shift away from the use of established TNF-inhibitors as first-line agents and towards the use of other biologics such as the IL-12/23 inhibitor Stelara, IL-17 inhibitors such as Cosentyx and Taltz, and IL-23 inhibitors such as Tremfya and Skyrizi.

Moreover, the rising awareness of the disease and better approaches to therapy development across the world will propel the moderate psoriasis market growth. Furthermore, the expected introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are likely to boost the growth of the Moderate Psoriasis market in the 7MM.

However, certain factors may affect the growth of the moderate psoriasis market. The moderate psoriasis market growth may be offset by unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the moderate psoriasis market growth.

Scope of the Moderate Psoriasis Market Report

• Therapeutic Assessment: Moderate Psoriasis current marketed and emerging therapies
• Moderate Psoriasis Market Dynamics: Attribute Analysis of Emerging Moderate Psoriasis Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Moderate Psoriasis Market Access and Reimbursement

Discover more about moderate psoriasis drugs in development @ Moderate Psoriasis Clinical Trials

Table of Contents

Related Reports

Moderate Psoriasis Epidemiology Forecast

Moderate Psoriasis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted moderate psoriasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Moderate Psoriasis Pipeline

Moderate Psoriasis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key moderate psoriasis companies, including Sun Pharmaceutical Industries Limited, Novartis Pharmaceuticals, UCB Pharma, AbbVie, Bristol-Myers Squibb, Ventyx Biosciences, Inc, among others.

Moderate to Severe Plaque Psoriasis Market

Moderate to Severe Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate to severe plaque psoriasis companies involved such as Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, among others.

Plaque Psoriasis Pipeline

Plaque Psoriasis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key plaque psoriasis companies involved such as Acrutis Biotherapeutics, AnaptysBio, Evelo Biosciences, Bristol-Myers Squibb, among others.

Plaque Psoriasis Market

Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key plaque psoriasis companies involved such as Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, among others.

Mild to Moderate Plaque Psoriasis Market

Mild to Moderate Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key mild to moderate plaque psoriasis companies involved such as Suzhou Zelgen Biopharmaceuticals, Acrutis Biotherapeutics, AnaptysBio, Evelo Biosciences, BMS, among others.

Other Trending Reports

Alopecia Market | Invasive Candidiasis Market | Bronchial Spasm Market | Chronic Gout Market | Hpv-Induced Cancers Market | Meningioma Market | Lewy Body Dementia Market | Anti-Gbm Disease Market | Colorectal Cancer CRC Market | Cervical Intraepithelial Neoplasia Market | Carpal Tunnel Syndrome Market | Nonalcoholic Steatohepatitis Market | AIDS Related Kaposis Sarcoma Market | Progressive Supranuclear Palsy Market | Tropical Spastic Paraparesis Market | Secondary Progressive Multiple Sclerosis SPMS Market | Systemic Sclerosis-Associated Interstitial Lung Disease Market | Reactive Airway Disease Market | Ptosis Market | AL Amyloidosis Market | Abdominal Aortic Aneurysm Market | X-Linked Retinitis Pigmentosa Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter